{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-149304","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2023-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.998316+00:00","generated_at":"2026-06-14T19:51:28.010276+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Prelude Therapeutics prices $100M public offering of common stock and pre-funded warrants","bullets":["Offering of 3.05M voting shares and 1.45M non-voting shares at $5.75/share; pre-funded warrants for 12.9M shares at $5.7499 each.","Gross proceeds $100M, net proceeds ~$98.5M; underwriter Morgan Stanley; expected close May 22, 2023.","Proceeds to advance pipeline (PRT2527, PRT1419, PRT3645, PRT3789) and new SMARCA2 oral molecule R&D.","Underwriters granted 30-day option to purchase up to 2.6M additional shares of common stock."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-149304","json":"https://secwatch.observer/filing/0001193125-23-149304.json","markdown":"https://secwatch.observer/filing/0001193125-23-149304.md","text":"https://secwatch.observer/filing/0001193125-23-149304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000119312523149304/0001193125-23-149304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000119312523149304/d407449d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T19:51:28.010276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"75bb80244c3fb2702ae6468b5952dce8b7dcf946","claim":"Prelude Therapeutics Inc entered into Underwriting Agreement with Morgan Stanley & Co. LLC (effective 2023-05-18).","evidence_excerpt":"On May 18, 2023, Prelude Therapeutics Incorporated (“ Prelude ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Morgan Stanley & Co. LLC as representative (the “ Representative ”) of the underwriters named therein (the “ Underwriters ”), pursuant to which Prelude agreed to issue and sell an aggregate of (a) 4,496,744 shares of its common stock, which comprise (i) 3,048,522 shares of its voting common stock, par value $0.0001 per share (the “ Voting Common Stock ”) and (ii) 1,448,222 shares of its non-voting common stock, par value $0.0001 per share (the “ Non-Voting Common Stock ,” and together with the Voting Common Stock, the “ Shares ”), at a price to the public of $5.75 per share, and (b) pre-funded warrants to purchase up to 12,895,256 shares of the Company’s Voting Common Stock (the “ Pre-Funded Warrants ”), at a price to the public of $5.7499 per warrant with an exercise price of $0.0001 per share (the “ Offering ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312523149304/0001193125-23-149304-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Morgan Stanley & Co. LLC"},{"label":"Effective","value":"2023-05-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}